[Asia Today] Heart Disease Diagnostic Medical Company AMCG Approved for New KONEX Listing

☞ Go to article

CEO Seo Yong-sung "KOSDAQ transfer listing within 2 years"

Heart disease diagnostic solution company AMCG has been listed on KONEX.

According to the company on the 13th, the Korea Exchange approved AMCG's new listing application submitted on November 20. The designated advisor for the listing is Daishin Securities.

AMCG was established in 2021 and has pursued commercialization after receiving Superconducting Quantum Interference Device (SQUID) technology and Magnetocardiography (MCG) system technology from the Korea Research Institute of Standards and Science (KRISS), a national standards agency. It is a company engaged in the heart disease diagnostic medical device business, having obtained item approvals from both domestic and US food and drug administrations.

MCG-S is currently installed in two hospitals and is undergoing post-marketing phase clinical trials to "evaluate the accuracy of MCG Scan for patients suspected of coronary artery disease." The company said, "We are focusing on obtaining new medical technology assessment in 2025 and health insurance coverage in 2026 through clinical results." The follow-up model, MCG-F, is being developed with lightweight technology, with the goal of obtaining domestic item approval in 2025 and introducing it to the rapidly growing health check-up market.

AMCG's magnetocardiography scanner measures extremely tiny magnetic signals (one billionth of the Earth's magnetic field) generated from the myocardium using SQUID (Superconducting Quantum Interference Device), a next-generation quantum sensor, to provide diagnostic information, and is attracting attention as a next-generation heart disease diagnostic device, according to the company.

Seo Yong-sung CEO of AMCG said, "Despite the unfavorable venture investment conditions in 2024, we have attracted 10 billion won in investment and secured 1.2 billion won in government contributions through Scale-up TIPS (R&D) projects, receiving recognition for our technology and business potential. The KONEX market listing will be an opportunity to grow as a global company in the field of early diagnosis of heart disease, with the goal of transferring to KOSDAQ within 2 years."

[Asia Today Kim Si-young Medical Specialist Reporter]